10/21/2026
Could continuous glucose monitoring help people with type 2 diabetes, including those who don’t use insulin?
Recently, we highlighted encouraging research on connected blood glucose meters. Now, new randomized evidence highlights the potential of a different technology: continuous glucose monitoring (CGM).
Published October 14 in the New England Journal of Medicine, the CONNECT trial enrolled 283 adults with type 2 diabetes who were not receiving insulin, across 22 US primary care practices.
At 26 weeks, CGM produced an adjusted 0.9-percentage-point greater reduction in HbA1c, a measure of longer-term blood sugar levels, than routine care.
Participants also spent approximately five additional hours each day within their target glucose range.
As the American Diabetes Association’s 2026 Standards of Care recognise, the pace and complexity of technological change can create barriers to implementation. Practices need the people and processes to make these tools work in everyday care.
🔵 At Vivo Care, we offer connected blood glucose meters as part of our services, bringing individual readings together with clinical support and follow-up.
As monitoring technology advances, one principle remains central: what happens after a reading matters. Turning readings into better care takes action.
Read the NEJM study:
https://www.nejm.org/doi/full/10.1056/NEJMoa2608571
ADA 2026 recommendations:
https://diabetesjournals.org/care/article/49/Supplement_1/S150/163922